Quality Longevity Science. Prediction Markets Treasury. One Nasdaq-Listed Structure.

Shai Novik is the co-founder and Executive Chairman of the Board of Enlivex Therapeutics (Nasdaq: ENLV), a clinical stage immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state as a potential novel therapy for life-threatening or debilitating diseases such as sepsis and osteoarthritis, which involve acute or chronic inflammation not resolvable by existing therapeutics. He previously founded (2005) and managed PROLOR Biotech, led its listing on the NYSE in 2010 and its sale in 2013, in a $560 million transaction.

Mr. Novik executed a strategic partnership with Pfizer for PROLOR’s lead drug product, Ngenla®, a deal that included a $295 million upfront payment, an additional $275 million upon regulatory approval and profit sharing at revenue stage. Ngenla® recently obtained marketing approvals in 43 countries, including Australia, Canada, Japan, Europe & United States, positioning Pfizer as the leader in the $4 billion global market for growth hormone deficiencies.

Mr. Novik is the co-founder and board member of Cortex Therapeutics, which is focused on developing and commercializing therapeutics anti-aging therapeutics for the eyes and the brain. Previously, Mr. Novik served as Chief Operating Officer, Head of Strategic Planning and Head of Investment Committee of THCG, Inc., a NYC-based technology and life sciences venture capital firm. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. Mr. Novik received his M.B.A, with distinction, from Cornell University.

Dr. Oren Hershkovitz has been serving as CEO of Enlivex Therapeutics Ltd since 2019. He is a seasoned biotech executive with over 15 years of experience in strategic and operational roles, leading the manufacturing, non-clinical and clinical development of various Phase I, II and III programs, including therapeutics for obesity, hemophilia and growth hormone deficiency. Prior to joining Enlivex, Dr. Hershkovitz was the General Manager of OPKO Biologics, Ltd., leading the late-stage development and collaboration with Pfizer of ngenla^TM, a drug which is currently approved for marketing in 43 countries, including Japan, EU and U.S. Dr. Hershkovitz has served for nearly a decade in managerial and executive roles at PROLOR Biotech, Inc. and OPKO Biologics, Ltd.

Dr. Hershkovitz received his Ph.D. in immunology, with distinction, from Ben-Gurion University.

Prof. Dror Mevorach, M.D., is the co-founder of Enlivex. As of 2009, Prof. Mevorach has served in various positions, including Chief Scientific & Medical Officer, and Scientific Adviser.

Prof. Mevorach is a leading scientist on the removal of apoptotic cells and Co-Chaired several Apoptotic Cell Recognition and Clearance sessions at the Gordon Research Conference and in international meetings.

Prof. Mevorach was the Chairman of Medicine and Department of COVID-19 at Hadassah Medical Center, and currently serves as the Director of the Institute of Rheumatology-Allergology and Immunology and Chairman of the Ethical Committee of Hadassah-Hebrew University Hospital and School of Medicine in Jerusalem.

Prof. Mevorach published more than 140 scientific papers and is a frequent lecturer at international conferences. Prof. Mevorach earned his M.D. (Cum Laude) from The Technion – Israel Institute of Technology in Haifa, Israel, and was a fellow at the Hospital for Special Surgery and Cornell Medical School, NY.

Einat Galamidi joined Enlivex in early 2022 to lead the clinical development programs, after over 10 years at Gamida Cell Ltd., where Dr. Galamidi most recently served as Vice President of Clinical Development, and head of clinical development for Omisirge®, a cell therapy for patients with hematologic malignancies planned for umbilical cord blood transplantation. Dr. Galamidi led the design and medical execution of the earlier studies of Omisirge®, as well as the pivotal phase 3 study which led to FDA granting approval of Omisirge® in April 2023.

Dr. Galamidi has over 2 decades experience in early and late-stage drug development, with particular involvement in clinical development of cellular therapies from first-in-man to registration studies for multiple clinical indications.

Dr. Veronique Amor-Baroukh has been with Enlivex Therapeutics since 2015.

In her current role as Chief Operating Officer she oversees the company’s operational activities, including CMC, Quality Control, Clinical Supply Chain, and Logistics. Previously, she led the CMC department, managing GMP activities and Process Development. Prior to that, she established and led the Process Development department, focusing on formulation development and process optimization, thereby leading the development of the frozen formulation of our allogeneic cell therapy Allocetra^TM.

Dr. Amor-Baroukh holds a Ph.D. and M.Sc. in Molecular Cell Biology from the Weizmann Institute of Science, and a B.Sc. Honors in Microbiology and Immunology from McGill University.

Shachar Shlosberger, CPA., has served as Enlivex’ Chief Financial Officer since 2016, bringing with her more than 12 years of financial experience in the hi-tech and biotechnology industries. Prior to her position at Enlivex, Mrs. Shlosberger worked for four years at PROLOR Biotech, Inc. as Finance Director where she was responsible for the overall financial operations in Israel and the United States. Ms. Shlosberger is a Certified Public Accountant and holds an M.B.A. degree in Accounting and Business Administration from the College of Management in Israel.

Mrs. Tavor holds an MSc. in Quality Engineering Biotechnology Systems. She has over 20 years of experience in Quality and Regulatory Affairs in the pharmaceutical and biotechnology industry, 13 of which at Pluristem Ltd., leading regulatory, strategic, and operational activities, throughout various clinical development programs, from pre-clinical stages through to Phase 3 studies.

Dr. Ankri has established the Pre-Clinical and Clinical pharmacology department at Enlivex. Dr. Ankri has several years of experience in Research and Development in the field of immunotherapy, and prior to joining Enlivex in 2020, has served as the Immunology Research manager at CTG Pharma.

Dr. Ankri obtained her Ph.D. in Cancer Immunotherapy at the Bar-Ilan University, Israel.

Mrs. Arad joined Enlivex in 2021 as Director of Human Resources. Mrs. Arad has over 15 years of experience in the biotech and scientific industry, 10 of which as the former HR manager of FutuRx – an accelerator for young biotechnology companies.

Mrs. Arad possess a B.Ed. and a Graduation Certificate from the Senior Human Resources program at Bar-Ilan University, Israel, and an Executive Consulting Certificate for HR managers.